文献速递免疫规划慢病防控与筛查

四价HPV疫苗不同剂次与间隔对重度宫颈病变的有效性

Effectiveness of varying number of doses and timing between doses of quadrivalent HPV vaccine against severe cervical lesions.
PubMed 文献 · Vaccine · 2018-09-21

基于丹麦和瑞典2006-2013年13-30岁女性人群队列(2,253,561人),研究四价HPV疫苗对CIN2+的保护效果。3剂次在13-16岁接种的IRR为0.23(95%CI 0.11-0.49),17-19岁为0.65(95%CI 0.41-1.03);13-16岁接种2剂且间隔≥5个月与3剂相比风险无差异。

要点

  • 13-16岁接种3剂qHPV者CIN2+风险IRR=0.23(95%CI 0.11-0.49),低于未接种者。
  • 17-19岁接种3剂者IRR=0.65(95%CI 0.41-1.03),低于未接种者。
  • 13-16岁2剂且间隔≥5个月者,CIN2+风险与3剂者无差异。

核心结论

  • 20岁前接种3剂qHPV者CIN2+风险降低,17岁前接种者风险进一步降低。
  • 13-16岁接种2剂且第二剂在第一剂后≥5个月,与3剂相比未增加CIN2+风险。

研究设计与样本

  • 基于丹麦和瑞典2006-2013年13-30岁全部女性的人群队列,随访qHPV接种状态和首次CIN2+发生。
  • 队列共2,253,561名女性,33%在随访期间接种,1.7%诊断为CIN2+。

主要发现

  • 13-16岁接种3剂者CIN2+风险IRR=0.23(95%CI 0.11-0.49),低于未接种者。
  • 17-19岁接种3剂者CIN2+风险IRR=0.65(95%CI 0.41-1.03),低于未接种者。
  • 接种1剂和2剂后CIN2+风险降低,但无统计学显著性。
  • 13-16岁接种2剂且两剂间隔≥5个月者,CIN2+风险与3剂者无差异。

关键数值与推荐

  • 13-16岁3剂:IRR=0.23(95%CI 0.11-0.49),对照为未接种。
  • 17-19岁3剂:IRR=0.65(95%CI 0.41-1.03),对照为未接种。

临床怎么用

  • 20岁前完成3剂qHPV接种可降低CIN2+风险,17岁前接种风险进一步降低。
  • 13-16岁接种2剂且第二剂间隔≥5个月,与3剂相比未增加CIN2+风险。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Based on immunogenicity studies, a 2 dose HPV vaccination-schedule was recently recommended for girls younger than 15 years. We aimed to investigate the effectiveness of quadrivalent HPV (qHPV) vaccination against CIN2 or worse (CIN2+), by age at vaccination, number of doses, and to test whether optimal timing of 2 doses of qHPV vaccine can confer the same level of protection as the originally recommended three dose-schedule. METHODS: A population-based cohort of all women aged 13-30 years, living in Denmark or Sweden during 2006-2013, was followed for qHPV vaccination status and first occurrence of CIN2+. RESULTS: The study cohort comprised 2,253,561 women, of which 33% were vaccinated during follow-up, and 1.7% were diagnosed with CIN2+. Vaccination at ages 13-16 and 17-19 was associated with a reduced risk of CIN2+ after 3 doses (IRR = 0.23, 95% CI 0.11-0.49, and IRR = 0.65, 95% CI 0.41-1.03, respectively), compared to being unvaccinated. After 1 and 2 doses there was a reduced risk, but not statistically significant. Women vaccinated ages 13-16 with 2 doses, where time between first and second dose was 5 months or longer showed no difference in risk compared to 3 doses. CONCLUSIONS: Women vaccinated with 3 doses of qHPV showed a reduced risk of CIN2+ if they were vaccinated before age 20, with a further reduced risk if vaccinated before age 17. Vaccination with 2 doses, with the second dose 5 months or longer after the first dose, did not yield an increased risk of CIN2+, compared to 3 doses.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Dehlendorff C, Sparén P, Baldur-Felskov B, et al. Effectiveness of varying number of doses and timing between doses of quadrivalent HPV vaccine against severe cervical lesions. Vaccine. 2018. PMID: 30249423. doi:10.1016/j.vaccine.2018.09.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。